Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
3,276
archived clinical trials in
Pancreatic Cancer

Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated:  10/20/2017
Glacier Oncology, PLLC
mi
from
Kalispell, MT
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated: 10/20/2017
Glacier Oncology, PLLC
mi
from
Kalispell, MT
Click here to add this to my saved trials
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated:  10/20/2017
Kalispell Medical Oncology at KRMC
mi
from
Kalispell, MT
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated: 10/20/2017
Kalispell Medical Oncology at KRMC
mi
from
Kalispell, MT
Click here to add this to my saved trials
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated:  10/20/2017
Kalispell Regional Medical Center
mi
from
Kalispell, MT
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated: 10/20/2017
Kalispell Regional Medical Center
mi
from
Kalispell, MT
Click here to add this to my saved trials
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated:  10/20/2017
Montana Cancer Specialists at Montana Cancer Center
mi
from
Missoula, MT
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated: 10/20/2017
Montana Cancer Specialists at Montana Cancer Center
mi
from
Missoula, MT
Click here to add this to my saved trials
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated:  10/20/2017
Montana Cancer Center
mi
from
Missoula, MT
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated: 10/20/2017
Montana Cancer Center
mi
from
Missoula, MT
Click here to add this to my saved trials
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated:  10/20/2017
CCOP - Missouri Valley Cancer Consortium
mi
from
Omaha, NE
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated: 10/20/2017
CCOP - Missouri Valley Cancer Consortium
mi
from
Omaha, NE
Click here to add this to my saved trials
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated:  10/20/2017
Creighton University Medical Center
mi
from
Omaha, NE
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated: 10/20/2017
Creighton University Medical Center
mi
from
Omaha, NE
Click here to add this to my saved trials
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated:  10/20/2017
Bismarck Cancer Center
mi
from
Bismarck, ND
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated: 10/20/2017
Bismarck Cancer Center
mi
from
Bismarck, ND
Click here to add this to my saved trials
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated:  10/20/2017
Medcenter One Hospital Cancer Care Center
mi
from
Bismarck, ND
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated: 10/20/2017
Medcenter One Hospital Cancer Care Center
mi
from
Bismarck, ND
Click here to add this to my saved trials
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated:  10/20/2017
Mid Dakota Clinic, PC
mi
from
Bismarck, ND
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated: 10/20/2017
Mid Dakota Clinic, PC
mi
from
Bismarck, ND
Click here to add this to my saved trials
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated:  10/20/2017
St. Alexius Medical Center Cancer Center
mi
from
Bismarck, ND
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated: 10/20/2017
St. Alexius Medical Center Cancer Center
mi
from
Bismarck, ND
Click here to add this to my saved trials
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated:  10/20/2017
Altru Cancer Center at Altru Hospital
mi
from
Grand Forks, ND
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated: 10/20/2017
Altru Cancer Center at Altru Hospital
mi
from
Grand Forks, ND
Click here to add this to my saved trials
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated:  10/20/2017
Geisinger Cancer Institute at Geisinger Health
mi
from
Danville, PA
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated: 10/20/2017
Geisinger Cancer Institute at Geisinger Health
mi
from
Danville, PA
Click here to add this to my saved trials
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated:  10/20/2017
Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center
mi
from
Wilkes-Barre, PA
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated: 10/20/2017
Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center
mi
from
Wilkes-Barre, PA
Click here to add this to my saved trials
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated:  10/20/2017
Rapid City Regional Hospital
mi
from
Rapid City, SD
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated: 10/20/2017
Rapid City Regional Hospital
mi
from
Rapid City, SD
Click here to add this to my saved trials
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated:  10/20/2017
Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center
mi
from
Green Bay, WI
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated: 10/20/2017
Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center
mi
from
Green Bay, WI
Click here to add this to my saved trials
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated:  10/20/2017
Green Bay Oncology, Limited at St. Mary's Hospital
mi
from
Green Bay, WI
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated: 10/20/2017
Green Bay Oncology, Limited at St. Mary's Hospital
mi
from
Green Bay, WI
Click here to add this to my saved trials
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated:  10/20/2017
St. Mary's Hospital Medical Center - Green Bay
mi
from
Green Bay, WI
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated: 10/20/2017
St. Mary's Hospital Medical Center - Green Bay
mi
from
Green Bay, WI
Click here to add this to my saved trials
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated:  10/20/2017
St. Vincent Hospital Regional Cancer Center
mi
from
Green Bay, WI
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated: 10/20/2017
St. Vincent Hospital Regional Cancer Center
mi
from
Green Bay, WI
Click here to add this to my saved trials
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated:  10/20/2017
Franciscan Skemp Healthcare - La Crosse Campus
mi
from
La Crosse, WI
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated: 10/20/2017
Franciscan Skemp Healthcare - La Crosse Campus
mi
from
La Crosse, WI
Click here to add this to my saved trials
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated:  10/20/2017
Holy Family Memorial Medical Center Cancer Care Center
mi
from
Manitowoc, WI
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated: 10/20/2017
Holy Family Memorial Medical Center Cancer Care Center
mi
from
Manitowoc, WI
Click here to add this to my saved trials
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated:  10/20/2017
Bay Area Cancer Care Center at Bay Area Medical Center
mi
from
Marinette, WI
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated: 10/20/2017
Bay Area Cancer Care Center at Bay Area Medical Center
mi
from
Marinette, WI
Click here to add this to my saved trials
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated:  10/20/2017
Door County Cancer Center at Door County Memorial Hospital
mi
from
Sturgeon Bay, WI
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated: 10/20/2017
Door County Cancer Center at Door County Memorial Hospital
mi
from
Sturgeon Bay, WI
Click here to add this to my saved trials
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated:  10/20/2017
Green Bay Oncology, Limited - Sturgeon Bay
mi
from
Sturgeon Bay, WI
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated: 10/20/2017
Green Bay Oncology, Limited - Sturgeon Bay
mi
from
Sturgeon Bay, WI
Click here to add this to my saved trials
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated:  10/20/2017
Rocky Mountain Oncology
mi
from
Casper, WY
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated: 10/20/2017
Rocky Mountain Oncology
mi
from
Casper, WY
Click here to add this to my saved trials
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated:  10/20/2017
Welch Cancer Center at Sheridan Memorial Hospital
mi
from
Sheridan, WY
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated: 10/20/2017
Welch Cancer Center at Sheridan Memorial Hospital
mi
from
Sheridan, WY
Click here to add this to my saved trials
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated:  10/20/2017
Lakeland Regional Cancer Care Center - St. Joseph
mi
from
Saint Joseph, MI
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting
Status: Enrolling
Updated: 10/20/2017
Lakeland Regional Cancer Care Center - St. Joseph
mi
from
Saint Joseph, MI
Click here to add this to my saved trials
Study of Sildenafil as a Therapy for Fatigue in Pancreatic Cancer
Phase I Assessment of NO Mediated Signaling in Cancer Cachexia
Status: Enrolling
Updated:  10/25/2017
University of Texas Medical Branch
mi
from
Galveston, TX
Study of Sildenafil as a Therapy for Fatigue in Pancreatic Cancer
Phase I Assessment of NO Mediated Signaling in Cancer Cachexia
Status: Enrolling
Updated: 10/25/2017
University of Texas Medical Branch
mi
from
Galveston, TX
Click here to add this to my saved trials
Capecitabine and Docetaxel in Treating Patients With Recurrent or Progressive Metastatic Pancreatic Cancer
A Multicenter Phase II Study of Capecitabine and Docetaxel for Previously Treated Pancreatic Cancer Patients "CapTere"
Status: Enrolling
Updated:  10/26/2017
Mayo Clinic, Jacksonville
mi
from
Jacksonville, FL
Capecitabine and Docetaxel in Treating Patients With Recurrent or Progressive Metastatic Pancreatic Cancer
A Multicenter Phase II Study of Capecitabine and Docetaxel for Previously Treated Pancreatic Cancer Patients "CapTere"
Status: Enrolling
Updated: 10/26/2017
Mayo Clinic, Jacksonville
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Capecitabine and Docetaxel in Treating Patients With Recurrent or Progressive Metastatic Pancreatic Cancer
A Multicenter Phase II Study of Capecitabine and Docetaxel for Previously Treated Pancreatic Cancer Patients "CapTere"
Status: Enrolling
Updated:  10/26/2017
Mount Sinai Comprehensive Cancer Center at Mount Sinai Medical Center
mi
from
Miami Beach, FL
Capecitabine and Docetaxel in Treating Patients With Recurrent or Progressive Metastatic Pancreatic Cancer
A Multicenter Phase II Study of Capecitabine and Docetaxel for Previously Treated Pancreatic Cancer Patients "CapTere"
Status: Enrolling
Updated: 10/26/2017
Mount Sinai Comprehensive Cancer Center at Mount Sinai Medical Center
mi
from
Miami Beach, FL
Click here to add this to my saved trials
Capecitabine and Docetaxel in Treating Patients With Recurrent or Progressive Metastatic Pancreatic Cancer
A Multicenter Phase II Study of Capecitabine and Docetaxel for Previously Treated Pancreatic Cancer Patients "CapTere"
Status: Enrolling
Updated:  10/26/2017
University of Miami
mi
from
Miami, FL
Capecitabine and Docetaxel in Treating Patients With Recurrent or Progressive Metastatic Pancreatic Cancer
A Multicenter Phase II Study of Capecitabine and Docetaxel for Previously Treated Pancreatic Cancer Patients "CapTere"
Status: Enrolling
Updated: 10/26/2017
University of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
Genistein, Gemcitabine, and Erlotinib in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
Phase II Trial of Novasoy®, Gemcitabine, and Erlotinib in Locally Advanced or Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  10/27/2017
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Genistein, Gemcitabine, and Erlotinib in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
Phase II Trial of Novasoy®, Gemcitabine, and Erlotinib in Locally Advanced or Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 10/27/2017
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
Genistein, Gemcitabine, and Erlotinib in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
Phase II Trial of Novasoy®, Gemcitabine, and Erlotinib in Locally Advanced or Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  10/27/2017
M. D. Anderson Cancer Center at University of Texas
mi
from
Houston, TX
Genistein, Gemcitabine, and Erlotinib in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
Phase II Trial of Novasoy®, Gemcitabine, and Erlotinib in Locally Advanced or Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 10/27/2017
M. D. Anderson Cancer Center at University of Texas
mi
from
Houston, TX
Click here to add this to my saved trials
Chemoradiation With Oxaliplatin and Fluorouracil (5FU) for Locally Advanced Pancreatic Cancer
A Phase I/II Study of Chemoradiation With Oxaliplatin and 5FU for Locally Advanced Pancreatic Cancer
Status: Enrolling
Updated:  10/30/2017
Bellevue Hospital
mi
from
New York, NY
Chemoradiation With Oxaliplatin and Fluorouracil (5FU) for Locally Advanced Pancreatic Cancer
A Phase I/II Study of Chemoradiation With Oxaliplatin and 5FU for Locally Advanced Pancreatic Cancer
Status: Enrolling
Updated: 10/30/2017
Bellevue Hospital
mi
from
New York, NY
Click here to add this to my saved trials
Chemoradiation With Oxaliplatin and Fluorouracil (5FU) for Locally Advanced Pancreatic Cancer
A Phase I/II Study of Chemoradiation With Oxaliplatin and 5FU for Locally Advanced Pancreatic Cancer
Status: Enrolling
Updated:  10/30/2017
NYU Cancer Institute
mi
from
New York, NY
Chemoradiation With Oxaliplatin and Fluorouracil (5FU) for Locally Advanced Pancreatic Cancer
A Phase I/II Study of Chemoradiation With Oxaliplatin and 5FU for Locally Advanced Pancreatic Cancer
Status: Enrolling
Updated: 10/30/2017
NYU Cancer Institute
mi
from
New York, NY
Click here to add this to my saved trials
Biospecimens for Identification of Diseases of the Pancreas.
Biospecimens for the Early Detection, Prevention, Diagnosis and Treatment of Diseases of the Pancreas.
Status: Enrolling
Updated:  11/6/2017
Univerisity of Michigan
mi
from
Ann Arbor, MI
Biospecimens for Identification of Diseases of the Pancreas.
Biospecimens for the Early Detection, Prevention, Diagnosis and Treatment of Diseases of the Pancreas.
Status: Enrolling
Updated: 11/6/2017
Univerisity of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
A Study of the GSK MEK Inhibitor GSK1120212 and Everolimus in Cancer Subjects
An Open-Label, Dose-Escalation, Phase IB II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor GSK1120212 in Combination With Oral Everolimus in Subjects With Solid Tumors
Status: Enrolling
Updated:  11/7/2017
GSK Investigational Site
mi
from
Nashville, TN
A Study of the GSK MEK Inhibitor GSK1120212 and Everolimus in Cancer Subjects
An Open-Label, Dose-Escalation, Phase IB II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor GSK1120212 in Combination With Oral Everolimus in Subjects With Solid Tumors
Status: Enrolling
Updated: 11/7/2017
GSK Investigational Site
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study of the GSK MEK Inhibitor GSK1120212 and Everolimus in Cancer Subjects
An Open-Label, Dose-Escalation, Phase IB II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor GSK1120212 in Combination With Oral Everolimus in Subjects With Solid Tumors
Status: Enrolling
Updated:  11/7/2017
GSK Investigational Site
mi
from
San Antonio, TX
A Study of the GSK MEK Inhibitor GSK1120212 and Everolimus in Cancer Subjects
An Open-Label, Dose-Escalation, Phase IB II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor GSK1120212 in Combination With Oral Everolimus in Subjects With Solid Tumors
Status: Enrolling
Updated: 11/7/2017
GSK Investigational Site
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Study of the GSK MEK Inhibitor GSK1120212 and Everolimus in Cancer Subjects
An Open-Label, Dose-Escalation, Phase IB II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor GSK1120212 in Combination With Oral Everolimus in Subjects With Solid Tumors
Status: Enrolling
Updated:  11/7/2017
GSK Investigational Site
mi
from
Paris Cedex 20,
A Study of the GSK MEK Inhibitor GSK1120212 and Everolimus in Cancer Subjects
An Open-Label, Dose-Escalation, Phase IB II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor GSK1120212 in Combination With Oral Everolimus in Subjects With Solid Tumors
Status: Enrolling
Updated: 11/7/2017
GSK Investigational Site
mi
from
Paris Cedex 20,
Click here to add this to my saved trials
Phase II Gemcitabine + Fractionated Stereotactic Radiotherapy for Unresectable Pancreatic Adenocarcinoma
Phase II Multi-Institutional Study to Evaluate the Efficacy of Gemcitabine and Fractionated Stereotactic Radiotherapy for Unresectable Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  11/20/2017
Stanford University School of Medicine
mi
from
Stanford, CA
Phase II Gemcitabine + Fractionated Stereotactic Radiotherapy for Unresectable Pancreatic Adenocarcinoma
Phase II Multi-Institutional Study to Evaluate the Efficacy of Gemcitabine and Fractionated Stereotactic Radiotherapy for Unresectable Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 11/20/2017
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
Phase II Gemcitabine + Fractionated Stereotactic Radiotherapy for Unresectable Pancreatic Adenocarcinoma
Phase II Multi-Institutional Study to Evaluate the Efficacy of Gemcitabine and Fractionated Stereotactic Radiotherapy for Unresectable Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  11/20/2017
Johns Hopkins Hospital
mi
from
Baltimore, MD
Phase II Gemcitabine + Fractionated Stereotactic Radiotherapy for Unresectable Pancreatic Adenocarcinoma
Phase II Multi-Institutional Study to Evaluate the Efficacy of Gemcitabine and Fractionated Stereotactic Radiotherapy for Unresectable Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 11/20/2017
Johns Hopkins Hospital
mi
from
Baltimore, MD
Click here to add this to my saved trials
Phase II Gemcitabine + Fractionated Stereotactic Radiotherapy for Unresectable Pancreatic Adenocarcinoma
Phase II Multi-Institutional Study to Evaluate the Efficacy of Gemcitabine and Fractionated Stereotactic Radiotherapy for Unresectable Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  11/20/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Phase II Gemcitabine + Fractionated Stereotactic Radiotherapy for Unresectable Pancreatic Adenocarcinoma
Phase II Multi-Institutional Study to Evaluate the Efficacy of Gemcitabine and Fractionated Stereotactic Radiotherapy for Unresectable Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 11/20/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors
Phase I Study of Bortezomib and Gemcitabine in Elderly Patients With Solid Tumors (X05227)
Status: Enrolling
Updated:  11/27/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors
Phase I Study of Bortezomib and Gemcitabine in Elderly Patients With Solid Tumors (X05227)
Status: Enrolling
Updated: 11/27/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors
Phase I Study of Sorafenib, Pemetrexed, and Cisplatin for the Treatment of Advanced Solid Tumors.
Status: Enrolling
Updated:  11/27/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors
Phase I Study of Sorafenib, Pemetrexed, and Cisplatin for the Treatment of Advanced Solid Tumors.
Status: Enrolling
Updated: 11/27/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Bortezomib and Cetuximab in Treating Patients With Advanced Solid Tumors
Phase I Study of Bortezomib (Velcade) and Cetuximab (Erbitux) for Patients With Solid Tumors Expressing EGFR
Status: Enrolling
Updated:  11/29/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Bortezomib and Cetuximab in Treating Patients With Advanced Solid Tumors
Phase I Study of Bortezomib (Velcade) and Cetuximab (Erbitux) for Patients With Solid Tumors Expressing EGFR
Status: Enrolling
Updated: 11/29/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Study of Pazopanib and Ixabepilone in Patients With Solid Tumors
Phase I Study of Pazopanib and Ixabepilone in Patients With Solid Tumors
Status: Enrolling
Updated:  12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Study of Pazopanib and Ixabepilone in Patients With Solid Tumors
Phase I Study of Pazopanib and Ixabepilone in Patients With Solid Tumors
Status: Enrolling
Updated: 12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy
Phase II Study of Panobinostat (LBH589) Given in Combination With Bortezomib (Velcade) in Patients With Pancreatic Cancer Progressing on Gemcitabine Therapy Alone or Gemcitabine in Combination
Status: Enrolling
Updated:  12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy
Phase II Study of Panobinostat (LBH589) Given in Combination With Bortezomib (Velcade) in Patients With Pancreatic Cancer Progressing on Gemcitabine Therapy Alone or Gemcitabine in Combination
Status: Enrolling
Updated: 12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Chemoradiation in Locally Advanced Pancreatic Cancer
A Phase II Pilot Study of Multi-Agent Neo-Adjuvant Chemoradiation in Patients With Locally Advanced Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Chemoradiation in Locally Advanced Pancreatic Cancer
A Phase II Pilot Study of Multi-Agent Neo-Adjuvant Chemoradiation in Patients With Locally Advanced Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Registry for Pancreatic Cancer
Registry to Evaluate Multi-modality Therapies for Pancreatic Cancer
Status: Enrolling
Updated:  12/4/2017
Duke University Health System
mi
from
Durham, NC
Registry for Pancreatic Cancer
Registry to Evaluate Multi-modality Therapies for Pancreatic Cancer
Status: Enrolling
Updated: 12/4/2017
Duke University Health System
mi
from
Durham, NC
Click here to add this to my saved trials
Registry for Pancreatic Cancer
Registry to Evaluate Multi-modality Therapies for Pancreatic Cancer
Status: Enrolling
Updated:  12/4/2017
Duke Univ Med Ctr
mi
from
Durham, NC
Registry for Pancreatic Cancer
Registry to Evaluate Multi-modality Therapies for Pancreatic Cancer
Status: Enrolling
Updated: 12/4/2017
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials